article thumbnail

Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet function [Cellular and Molecular]

ASPET

Significance Statement This study examines the effects of clinically relevant small molecule BCR-ABL tyrosine kinase inhibitors (TKIs) on platelet activity. Overall, these new insights around the effects of ABL TKIs on platelet function could inform the development of targeted therapies with reduced hematologic toxicities.

article thumbnail

Redirecting the pioneering function of FOXA1 with covalent small molecules

Covalent Modifiers

Our findings reveal a striking plasticity underpinning the pioneering function of FOXA1 that can be controlled by small molecules. Motif analysis supports a mechanism where the ligands relax the canonical DNA-binding preference of FOXA1 by strengthening interactions with suboptimal sequences in predicted proximity to C258.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Small Molecule of the Year – 2022

Drug Hunter

Through a series of structure-based design, ADME and solubility optimization, LP0200 was shown to exhibit high potency and safety comparable to approved IL-17A and IL-17RA targeting mAbs (more in our report of first disclosures from the EFMC-ISMC and this article on small molecule immunomodulators ). LP0200 has completed a Ph.

article thumbnail

Redirecting the pioneering function of FOXA1 with covalent small molecules

Covalent Modifiers

Here, we report the chemical proteomic discovery of electrophilic small molecules that stereoselectively and site-specifically bind the pioneer TF, FOXA1, at a cysteine (C258) within the forkhead DNA-binding domain. Chemical probes are lacking for pioneer TFs, which has hindered their mechanistic investigation in cells.

article thumbnail

Interactions of small molecule inhibitors with secreted phospholipase A2: A review of the structural data

Chemical Biology and Drug Design

Knowledge of the molecular interactions acquired from such structures would greatly aid the discovery of small molecule inhibitors of sPLA 2 s for the treatment of snakebite envenoming. In addition, the complex of the sPLA 2 inhibitor, varespladib, with a Lys49-PLA 2 -like snake venom toxin is also discussed.

article thumbnail

Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases

Covalent Modifiers

Liang Ouyang, Wen Shuai, Panpan Yang, Huan Xiao, Yumeng Zhu, Faqian Bu, Aoxue Wang, Qiu Sun, Guan Wang Angewandte Chemie 2024 e202411037 [link] c-Jun N-terminal kinases (JNKs) including JNK1/2/3 are key members of mitogen-activated protein kinase family.

article thumbnail

Development of a Covalent Small Molecule Downmodulator for the Transcription Factor Brachyury

Covalent Modifiers

Herein, we use afatinib as a lead to undertake a structure-based drug design approach, aided by mass-spectrometry and x-ray crystallography, to develop DHC-156, a small molecule that more selectively binds brachyury and downmodulates it as potently as afatinib.